Newly Designated NCI Director Roundly Applauded by Cancer Community

Publication
Article
OncologyONCOLOGY Vol 16 No 2
Volume 16
Issue 2

The cancer community is expressing unanimous approval of President George W. Bush’s appointment of Andrew von Eschenbach, MD, as director of the National Cancer Institute (NCI). Dr. von Eschenbach was director of the Genitourinary Cancer Center and Prostate Cancer Research Program at the University of Texas M. D. Anderson Cancer Center. "[His] extensive experience in cancer research, treatment, and prevention has prepared him extraordinarily well to head the NCI," said Larry Norton, MD, president of the American Society of Clinical Oncology. "As both a recognized leader in the oncology community and as a cancer survivor, Andy brings a distinctive perspective to this position."

The cancer community is expressing unanimous approvalof President George W. Bush’s appointment of Andrew von Eschenbach, MD, asdirector of the National Cancer Institute (NCI). Dr. von Eschenbach was directorof the Genitourinary Cancer Center and Prostate Cancer Research Program at theUniversity of Texas M. D. Anderson Cancer Center. "[His] extensiveexperience in cancer research, treatment, and prevention has prepared himextraordinarily well to head the NCI," said Larry Norton, MD, president ofthe American Society of Clinical Oncology. "As both a recognized leader inthe oncology community and as a cancer survivor, Andy brings a distinctiveperspective to this position."

Dr. Von Eschenbach has also been active in the American Cancer Society (ACS).He served recently as president-elect of the ACS’s national volunteer Board ofDirectors. John R. Seffrin, the ACS’s national chief executive officer, said,"As the chair of our cancer control committee and numerous other postswithin the Society throughout the years, Dr. von Eschenbach has proven hiscompassion and commitment to eradicating cancer as a major health threat hereand now. The National Cancer Institute will do well by his leadership andpassion."

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content